The PI3K/AKT/mTOR pathway is hyperactivated in >40% of CRC cases, and its inhibition by agents like pictilisib has shown limited clinical efficacy due to feedback activation of parallel pathways (Cancer Genome Atlas Network, 2012). This evidence concerns the gene PIK3CA and colorectal carcinoma.